Back to Immunity
SupplementModerate evidenceImmunity

Soy isoflavones

Phytoestrogen meta-analysis support for menopausal hot flush reduction, modest, slow onset, requires daidzein-equol metaboliser status.

Why

Soy isoflavones (genistein, daidzein, glycitein) have been studied for menopausal vasomotor symptoms for two decades. The Taku 2012 Menopause meta-analysis reported a 20.6% reduction in hot flush frequency and a 26.2% reduction in severity at ≥54 mg/day genistein-equivalents. Effect is more consistent in equol-producers (a subset of women whose gut microbiota convert daidzein to the more potent equol). EFSA has not yet authorised a hot-flush claim, citing methodological heterogeneity.

How it works

Isoflavones bind preferentially to oestrogen receptor β (vs α), producing tissue-selective oestrogenic effects, SERM-like. Equol (gut bacterial metabolite of daidzein) has stronger ER-β affinity than the parent isoflavone, and equol-producers show larger clinical effects.

Expected onset · Vasomotor effect emerges over 8–12 weeks

How to take

Dosage

≥54 mg/day genistein-equivalents from standardised extract for hot flush effect. Dietary intake from soy foods provides ~25–50 mg/day in soy-consuming populations.

Timing

Once daily with food

On the label

Standardised genistein and daidzein content per serving. Fermented soy (natto, miso, tempeh) and red clover (separate card) are alternative isoflavone sources.

Ideal for

Postmenopausal women with troublesome vasomotor symptoms seeking a phytoestrogen approach.

Safety

Avoid in oestrogen-sensitive malignancy (breast, endometrial, ovarian), phytoestrogen activity is real, even though epidemiology in soy-consuming populations is reassuring. Caution with tamoxifen and aromatase inhibitors. Possible interaction with thyroid medication absorption. Separate by 2 hours. Pregnancy and breastfeeding: dietary soy is fine; supplement doses should be avoided.

Evidence

At a glance

Taku 2012 Menopause meta-analysis (19 RCTs, n=1,278): soy isoflavones ≥54 mg/day reduced daily hot flush frequency by ~20% and severity by ~26%. Effect smaller than HRT but consistent in direction. Equol-producer status (about 30–50% of women) appears to predict response, a personalisation factor.

Where to get it

Shop Soy isoflavones on Amazon

Sponsored · As an Amazon Associate, Healicus earns from qualifying purchases.